Mouse Monoclonal CD105 Antibody

CD105 antibody targets endoglin, a transmembrane glycoprotein primarily expressed on vascular endothelial cells. Endoglin functions as a co-receptor in the transforming growth factor-beta (TGF-β) signaling pathway, particularly interacting with TGF-β1 and TGF-β3 ligands. It modulates cellular responses by forming complexes with type I (ALK1/ALK5) and type II TGF-β receptors, influencing angiogenesis, vascular remodeling, and endothelial cell proliferation. CD105 is a recognized marker for activated endothelial cells, making it valuable in studying pathological angiogenesis in cancers, cardiovascular diseases, and inflammatory conditions. Its overexpression in tumor-associated vasculature has driven its use in cancer research for assessing microvessel density and anti-angiogenic therapy efficacy. Additionally, CD105 antibodies are employed in flow cytometry and immunohistochemistry to identify proliferating endothelial cells in tissues. Beyond research, CD105-targeted imaging agents and therapeutics are under exploration for diagnosing and treating diseases marked by abnormal vascularization. Mutations in the endoglin gene (ENG) are linked to hereditary hemorrhagic telangiectasia (HHT), a vascular dysplasia disorder, highlighting its clinical relevance. The antibody’s specificity and functional role in vascular biology continue to make it a critical tool in both basic research and translational applications.